Skip to main content

Table 1 Clinical characteristics of patients with papillary thyroid cancer

From: Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies

Sample No

Sex

Age (years)

Tumor size (cm)

BRAF mutation

Tumor stage

Node stage

Clinical stage

PTC-1

Female

60

1.0 × 0.7 × 0.3

 + 

T1

N0

I

PTC-2

Female

33

2.2 × 1.4 × 1.4

 + 

T2

N1a

I

PTC-3

Male

34

1.9 × 1.5 × 1.2

 + 

T1b

N1a

I

PTC-4

Male

33

3.0 × 2.4 × 1.6

 + 

T3

N0

I

PTC-5

Male

20

1.9 × 1.6 × 1.0

 + 

T1b

N1b

I

PTC-6

Female

28

3.5 × 2.3 × 1.8

 − 

T2

N1b

I

PTC-7

Female

31

2.5 × 2.0 × 2.0

 − 

T2

N0

I

PTC-8

Female

27

2.1 × 1.6 × 1.5

 − 

T1b

N1a

I

PTC-9

Male

32

3.5 × 3.0 × 3.0

 − 

T2

N1

I